Novartis’ Afinitor has significantly reduced treatment-resistant seizures in patients with tuberous sclerosis complex (TSC) taking part in the Phase III EXIST-3 trial.
News
Three million using health innovations under NHS scheme
Three million patients began tapping into new apps, safety devices, on-line networks, and a stream of other new technologies and services during the first nine months of a pioneering programme designed to introduce new innovations to the NHS.
New trial tests use of metformin to prevent diabetes type I
A major clinical trial has kicked off in Scotland to investigate prophylactic use of metformin as a means of staving off type I diabetes in children.
BMS Opdivo extends survival in head and neck cancer trial
Bristol-Myers Squibb’s immunotherapy Opdivo has shown a significant survival benefit in a late-stage trial assessing its potential in patients with metastatic squamous cell carcinoma of the head and neck.
GSK kicks off hand osteoarthritis trial
GlaxoSmithKline has begun enrolling patients in a mid-stage trial assessing the safety and efficacy of an experimental therapy for hand osteoarthritis licensed from MorphoSys.
Two-fifths of Parkinson’s patients hiding their diagnosis
A significant proportion of patients with Parkinson’s disease are hiding their symptoms or diagnosis from family or friends for fear or embarrassment of being judged, a survey for charity Parkinson’s UK has revealed.
BI exercises deal option for Oxford BioTherapeutics’ target
Boehringer Ingelheim has exercised an option that gives it exclusive rights to an undisclosed oncology target from its discovery collaboration with Oxford BioTherapeutics.
Another US ‘breakthrough’ status for Merck’s Keytruda
US regulators have awarded Merck’s immunotherapy Keytruda another breakthrough badge, this time for the treatment of relapsed or refractory classical Hodgkin lymphoma, potentially further speeding up the regulatory pathway for the drug in this indication.
BMA highlights concerns over NHS private providers
More than two-thirds of doctors are uncomfortable with the use of private providers for NHS services, according to a new report by the British Medical Association.
AstraZeneca eyeing up Medivation?
AstraZeneca is considering making a move on US group Medivation in a deal that could be worth around $7 billion, according to media reports.
BMS’ Opdivo shows ‘unprecedented’ survival benefit in trials
Bristol-Myers Squibb has unveiled clinical data from the first randomised study to evaluate Opdivo and Yervoy in combination in patients with previously untreated advanced melanoma, showing a strong survival benefit.
NICE recommends PTC’s Duchenne drug
The National Institute for Health and Care Excellence has recommended PTC Therapeutics’ Translarna for some patients with Duchenne muscular dystrophy, but only in connection with a managed access agreement (MAA) being drawn up with NHS England.
US widens use of Boehringer’s lung cancer drug Gilotrif
US health officials have expanded the approved indications for Boehringer Ingelheim’s Gilotrif, clearing its use in patients with squamous cell carcinoma of the lung.
Merck’s Zepatier shows high response rates in hep C trials
Merck’s hepatitis C drug Zepatier has induced cure rates as high as 96 percent across two niche patient populations investigated in Phase III trials, according to data presented at The International Liver Congress.
BMS’ Opdivo gets priority review for classical Hodgkin lymphoma
Bristol-Myers Squibb’s immunotherapy Opdivo has taken a step towards the US market for classical Hodgkin lymphoma (cHL) after regulators accepted an application for its use in pre-treated patients.
